2.1 C
New York
Friday, February 3, 2023

There Is A Quest For Clarity Surrounding Bright Minds Biosciences Inc. (NASDAQ: DRUG) Volatility

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Bright Minds Biosciences Inc. (DRUG) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.01, or -0.88%, to $1.13. The Bright Minds Biosciences Inc. has recorded 2,659 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Bright Minds Biosciences Announces Non-Brokered Private Placement.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Stocks Info

This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $1.14 and fluctuated between $1.1900 as its day high and $1.0600 as its day low. The current market capitalization of Bright Minds Biosciences Inc. is $18.72M. A total of 0.58 million shares were traded on the day, compared to an average of 2.71M shares.

Insider trades can also provide insight into a stock’s future direction. During the recent three months, DRUG has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 12 BUYs and 1 SELLs from insiders. Insiders purchased 8,500 shares during that period but sold 10,000.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for DRUG in the last 3 months, the mean price target is $9.09 with high estimates of $9.09 and low estimates of $9.09. In terms of 52-week highs and lows, DRUG has a high of $4.75 and a low of $0.75.

As of this writing, DRUG has an earnings estimate of $0 per share for the current quarter. EPS was calculated based on a consensus of 0 estimates, with a high estimate of $0 per share and a lower estimate of $0.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 1 analysts are providing their opinions on the stock. A total of 1 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles